Datavault AI 凭借新获颁专利及专利授权通知进一步扩展知识产权组合 ACN Newswire

Datavault AI 凭借新获颁专利及专利授权通知进一步扩展知识产权组合

宾夕法尼亚州费城, 2026年4月22日 - (亚太商讯 via SeaPRwire.com) - Datavault AI Inc.(“Datavault AI”或“公司”) (纳斯达克代码:DVLT),作为人工智能驱动的数据变现、资质认证、数字互动及现实世界资产(“RWA”)通证化技术的领导者,今日宣布获得美国专利第12,596,819号,并收到两项美国专利申请的准予通知。这一里程碑直接延续了公司于2025年12月获得的两项基础专利——区块链驱动的内容授权及代币化变现专利,进一步扩展了其强大的知识产权组合,其中以行业标杆性的碳信用代币化专利为代表。投资者关注要点一项新颁发的专利和两份准予通知书将保护范围扩展至三个高价值平台:AI验证的数据估值与变现、代币化虚拟位置融资,以及数字资产和DeFi的自动化纳税申报准备——直接解决了1099-DA合规挑战。通过抗量子加密和区块链不可篡改性,强化了公司的Sumerian®加密锚、DataValue®、DataScore®及信息数据交换®(IDE®)技术,为日益增长的代币化合约和授权协议提供了坚实支撑。该产品问世之际,正值首个完整的 IRS 1099-DA 申报季结束,此前据报道存在运营障碍——包括 Coinbase、Kraken 和 Gemini 的数据提交延迟——这充分证明了市场对 Datavault AI 自动化、代币化税务解决方案的明确需求。支持的应用场景包括代币化大宗商品(铜、黄金、贵金属)、农业/基因组/医疗数据资产、NIL数字孪生、资金支持的虚拟生物技术市场,以及智能税务自动化——这些功能可与公司的边缘GPU集群和HPC基础设施原生集成。该技术直接支撑Datavault AI实现2026年至少2亿美元营收的目标,加速其在金融科技、医疗保健、生物技术、能源、农业、体育娱乐及Web3领域的商业化进程,并开辟新的授权与合作机遇。最新专利保护范围美国专利号 12,596,819 - “数据估值与安全商业变现平台的方法及系统”(已授权):涵盖端到端的许可型平台,涵盖自愿数据贡献、AI驱动的自动化估值、在Datavault®中的区块链代币化存储,以及在开放交易所上的交易(支持销售、许可、奖励、慈善捐赠等多种灵活的补偿途径)。美国专利申请号 17/842,220 - “虚拟位置融资系统及方法”(准予通知):保护针对特定组织的虚拟位置的融资、认证及代币化运营,包括多币种捐赠、集成式活动与资产代币化、与投资组合匹配的广告,以及面向数据贡献者的补偿机制。美国专利申请号 17/507,459 - “报税准备平台及方法”(准予通知):涵盖为客户和员工提供的自动化报税准备服务,包含针对数字资产和DeFi活动的专用代币化报税处理、后端表单处理,以及对不断变化的税法进行的动态调整——精准解决困扰首个1099-DA申报季的对账负担和可见性缺口。市场背景与利好因素这些专利申请使 Datavault AI 处于三个快速扩张市场的交汇点。代币化的现实世界资产(RWA)的链上价值已超过 300 亿美元(RWA.xyz 2025 年数据),波士顿咨询集团(BCG)和 ADDX 预测,到 2030 年全球市场规模将超过 16 万亿美元。全球数据货币化市场预计将从2024年的75.3亿美元增长至2033年的188亿美元(年复合增长率10.7%,SkyQuest Technology)。这项新的税务申报专利恰逢美国纳税人正经历美国国税局(IRS)1099-DA表数字资产经纪商申报制度实施后的首个完整纳税年度——其中总收入申报自2025年1月1日开始,特定交易的成本基础申报将于2026年1月1日生效——而行业内关于经纪商申报延迟以及跨钱包/跨链/跨DeFi对账的摩擦问题已广受关注。对投资者的影响与战略展望总体而言,已获授权的专利和获准的专利申请扩展了知识产权的覆盖范围,涵盖了将原始数据转化为代币化、可交易资产的创新技术,并实现了虚拟环境及数字资产组合的透明融资、变现和自动化税务处理。预计这些技术将与 Datavault AI 计划部署的边缘 GPU 集群和高性能计算基础设施无缝集成,从而加速 AI 估值处理和代币化合约的执行。“获得这项已授权专利并收到另外两项申请的准予通知,印证了我们在将无形数据转化为可验证、可变现资本方面的领导地位,以及在帮助组织以完全透明且用户可获补偿的方式为虚拟世界提供资金并运营方面的优势,”Datavault AI创始人兼首席执行官纳撒尼尔·T·布拉德利(Nathaniel T. Bradley)表示。“这些专利申请深化了我们的竞争护城河,并加速了我们在数据资产、实物资产及数字资产税务准备市场中抢占重要份额的进程——这将直接推动我们实现2026年2亿美元的营收目标,并扩大代币化合约的储备。”如需进一步了解 Datavault AI 的增长战略、商业化路线图,以及通过代币化和授权释放数据与知识产权价值的长期愿景,建议投资者观看 Tech Edge 近期对首席执行官纳撒尼尔·布拉德利(Nathaniel Bradley)的纳斯达克专访,该视频现已发布于 https://vimeo.com/1176174810 关于 Datavault AI Inc.Datavault AI™(纳斯达克代码:DVLT)是 Web 3.0 环境中人工智能驱动的数据体验、资产估值及货币化领域的先驱。公司基于云的平台通过其声学科学和数据科学两大部门提供全面解决方案。Datavault AI的声学科学部门拥有WiSA®、ADIO®和Sumerian®等专利技术,专用于空间及多声道无线高清音频传输。数据科学部门则利用Web 3.0和高性能计算技术,在体育娱乐、生物技术、教育、金融科技、房地产、医疗保健、能源等众多行业中,实现体验式数据感知、估值及安全变现。信息数据交易所®(IDE®)是由纳斯达克金融基础设施公司(Nasdaq Financial Infrastructure)提供技术支持的代币交易所。该公司拥有并运营多家交易所,包括国际元素交易所(IEE)、体育画报交易所(SIx)、纽约互动广告交易所(NYIAX)以及美国政治交易所(APE)。公司总部位于宾夕法尼亚州费城。更多信息请访问 https://www.dvlt.ai。前瞻性陈述:本新闻稿包含《1933年证券法》(经修订)第27A条、《1934年证券交易法》(经修订)第21E条以及《1995年私人证券诉讼改革法案》所界定的“前瞻性陈述”。本新闻稿中除历史事实陈述以外的所有陈述,包括关于公司未来运营、财务状况、前景、计划、目标、预期及意图的陈述,均属前瞻性陈述。诸如“预期”、“相信”、 “可能”、“估计”、“预期”、“打算”、“或许”、“计划”、“潜在”、“预测”、“预测”、“应”、“目标”、“将”、“会”等词语及类似表述旨在识别前瞻性陈述,尽管并非所有前瞻性陈述都包含这些识别性词语。本新闻稿中的前瞻性陈述包括但不限于以下内容:(i) 美国专利申请号 17/842,220、美国专利申请号 17/507,459 以及任何相关外国或延续申请的最终授权、范围、有效性和可执行性; (ii) 本公司已获专利及正在申请专利的技术的商业价值、市场采用情况及收入贡献,包括DataValue®、DataScore®、信息数据交换®(IDE®)、Sumerian®加密锚点以及Datavault®平台; (iii) 本公司实现2026年至少2亿美元营收目标的能力;(iv) 本公司正在推进的代币化合同、许可协议及战略合作伙伴关系; (v) 代币化实物资产、数据变现及数字资产税务申报市场的规模、增长态势及发展时机;(vi) 公司预期部署的边缘GPU集群及高性能计算基础设施的集成与运行表现;以及 (vii) 因美国国税局1099-DA表格申报要求而产生的自动化税务申报解决方案需求。这些前瞻性陈述基于管理层目前的预期和假设,并受重大风险、不确定性及其他因素的影响,这些因素可能导致实际结果与明示或暗示的结果存在重大差异。此类风险包括但不限于:美国专利商标局在复审时将已获授权的权利要求范围缩小,或驳回已获授权的权利要求;本公司专利及专利申请中技术的商业化进程出现延迟或失败;本公司吸引和留住客户、被许可方及交易所合作伙伴的能力;来自现有及新兴技术的竞争; 网络安全、区块链协议及量子计算风险;影响数字资产申报的美国联邦及州税法变更(包括对1099-DA表格制度的修改);影响数字资产、证券、数据隐私及代币化实物资产的监管动态; 本公司按可接受条款筹集额外资金的能力;宏观经济及资本市场状况;以及本公司截至2025年12月31日财政年度的10-K表年度报告、后续10-Q表季度报告、 8-K表当前报告以及向美国证券交易委员会(“SEC”)提交的其他文件中讨论的其他风险因素,上述文件的副本可免费从SEC网站www.sec.gov获取。除适用法律要求外,本公司不承担任何义务,并明确声明不负有任何责任,无论因新信息、未来事件、情况变化或其他原因,均不更新或修订任何前瞻性陈述。投资者和证券持有人应注意,切勿过度依赖这些前瞻性陈述,因其仅反映本新闻稿发布之日的状况。本公司不保证其预期能够实现。本新闻稿不构成出售任何证券的要约,亦不构成购买任何证券的要约邀请。关于潜在收购、处置、合资企业、战略联盟、许可交易或类似安排的任何前瞻性陈述,均受最终协议的谈判、签署和履行以及惯常交割条件的满足所制约,且无法保证此类交易将按预期条款、预期时间完成,甚至可能无法完成。行业与市场数据:本新闻稿包含基于或源自独立行业出版物、第三方研究、调查及报告的行业、市场及竞争地位数据,包括统计数据、预测及推算,其中涉及RWA.xyz、波士顿咨询集团(Boston Consulting Group)、ADDX、SkyQuest Technology以及美国国税局(U.S. Internal Revenue Service)提供的数据。本公司未独立核实此类第三方信息的准确性或完整性,且对其可靠性不作任何明示或暗示的陈述或保证。此类行业出版物及预测本质上受制于假设、方法论限制及不确定性,基于此类数据的推测、估计及判断可能并不准确。实际市场规模、增长率以及本公司在这些市场中的地位可能与本文所述数据存在重大差异。商标、商号、服务标记及版权:Datavault AI™、DataValue®、DataScore®、Information Data Exchange®、IDE®、Datavault®、WiSA®、ADIO® 及 Sumerian® 是 Datavault AI Inc. 在美国及/或其他司法管辖区的商标、服务标记或注册商标。本新闻稿还涉及其他公司拥有的商标、服务标记、商号及版权,包括 Coinbase、Kraken、Gemini 和 Nasdaq 的相关标识。仅为方便起见,本新闻稿中提及的某些商标、服务标记、商号及版权可能未标注™、®、©或SM符号,但本公司将在适用法律允许的最大范围内,对其自有商标、服务标记、商号及版权主张权利。使用或展示其他方的商标、服务标记、商号或版权,并非旨在且不暗示本公司与任何此类第三方存在关系,亦不构成对该等第三方的认可或赞助。媒体联系:marketing@dvlt.ai 投资者联系:Edward Barger投资者关系副总裁ebarger@dvlt.ai | ir@dvlt.ai 来源:Datavault AI Inc Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
China Gas Signs Strategic Cooperation Agreement with CITIC Construction and China CITIC Bank JCN Newswire

China Gas Signs Strategic Cooperation Agreement with CITIC Construction and China CITIC Bank

HONG KONG, Apr 22, 2026 - (ACN Newswire via SeaPRwire.com) - China Gas Holdings Limited (“China Gas” or the “Group”; stock code: 384), a leading city gas operator in China, announced that it has entered into a strategic cooperation agreement with CITIC Construction Co., Ltd. (“CITIC Construction”) and China CITIC Bank Corporation Limited (“China CITIC Bank”). Based on the principles of “resource sharing, complementary strengths, shared benefits and mutual success”, the three parties will establish an integrated “industry-construction-finance” ecosystem-based collaborative model. This partnership aims to further support the development of China Gas’ new businesses, including energy storage and biomass energy, and jointly deepening engagement in global energy infrastructure and green low-carbon industries.China Gas, CITIC Construction and China CITIC Bank officially sign a tripartite strategic cooperation agreementThis collaboration represents an important step by all parties in actively responding to China’s “15th Five-Year Plan” and deepply participating in the Belt and Road Initiative. According to the agreement, the three parties will establish a comprehensive strategic partnership and conduct in-depth cooperation across various areas, including overseas energy infrastructure construction, joint development of third-party projects, industrial park businesses, green finance and various financing collaborations. They have adopted a closed-loop, ecosystem-based collaborative model: China Gas serves as the business model leader, responsible for project planning, technical solutions, and operations; CITIC Construction acts as the engineering and construction executor, leveraging its strengths in local resource coordination and construction management; China CITIC Bank, as the financial services provider, will meetinvestment and financing needs.To address global climate change and energy security challenges, the three parties will focus on the core areas, including: i) Prioritizing high-potential regions including Europe, Southeast Asia, Central Asia, and North Asia to jointly promote the development and construction of energy infrastructure, ii) Integrating their resources around the industrial parks and new urbanization projects led and developed by China Gas at home and abroad, iii) Working together to implement the “green development” strategy and engage in in-depth collaboration in the areas of investment and financing.To capitalize on the opportunities presented by the global energy transition and the national “dualcarbon” goals, the Group is accelerating the development of two new growth drivers: its new energy business centered on energy storage and its biomass energy business. In the energy storage sector, the Group is seizing the strategic opportunities created by power market reforms and the development of a new power system, while continuing to deepen its market presence and optimize its layout, with a focus on “concentrating efforts in core regions and achieving key breakthroughs in overseas markets”. Meanwhile, the Group is actively expanding its biomass business and achieving growth across multiple fronts. It has previously entered cooperation agreements with several leading enterprises, including Deyi Energy (a subsidiary of Chery Automobile) and EVE Energy, as well as local governments, to jointly advance the construction of zero-carbon industrial parks and the clean upgrading of industries. This cooperation will further support the Group in expanding its domestic and overseas markets, focusing on the two new growth engines of “energy storage + biomass energy”, and promoting the Group’s healthy and sustainable development.Mr. LIU Ming Hui, Chairman and President of China Gas, said, “After more than two decades of development, China Gas has built a comprehensive business structure centered on natural gas, integrating LNG, LPG, biomass energy, and new energy technology. We are currently accelerating our globalization strategy and have formed a clear business footprint in regions such as Europe, Southeast Asia, Central Asia, and North Asia. The signing of this tripartite agreement with CITIC Construction and China CITIC Bank marks our shift from simple overseas expansion to a cluster-based international strategy driven by industry leadership, empowered by engineering expertise, and finance support. Through close collaboration with our partners in finance and industry, we will leverage our stronger risk resilience and our industry chain advantages to contribute China Gas solutions to the sustainable development of global energy.”About China Gas Holdings LimitedChina Gas Holdings Limited ("China Gas", stock code: 384. HK) is a leading gas service provider. Focusing on China, it principally specializes in the investment, construction and operations of city gas pipeline infrastructure, distribution of natural gas and LPG to residential, industrial and commercial users, as well as construction and operations of gas refilling stations for vehicles and vessels. Currently, China Gas owns a total of 662 city and township gas projects with concession rights, 32 long-distance pipeline transmission projects of natural gas, 485 CNG and LNG refilling stations for vehicles and vessels, as well as 120 LPG distribution projects. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
More
CBL International Limited Acquires Majority Stake in Green Marine Energy Holdings Limited JCN Newswire

CBL International Limited Acquires Majority Stake in Green Marine Energy Holdings Limited

Kuala Lumpur, Apr 22, 2026 - (ACN Newswire via SeaPRwire.com) — CBL International Limited (NASDAQ: BANL) (“CBL” or the “Company”), a Nasdaq-listed marine fuel logistics and bunkering facilitator of Banle Group (“Banle” or “the Group”) focused on the Asia-Pacific region, today announced the acquisition of a 50.5% majority stake in Green Marine Energy Holdings Limited (“GMH”), a British Virgin Islands incorporated company. The transaction will be executed by CBL’s wholly-owned subsidiary, which has signed the Share Sale and Purchase Agreement (the “SPA”) as the buyer. To support the transaction, CBL will provide a corporate guarantee to the sellers, securing the payment obligations of its subsidiary.GMH operates two complementary businesses in Malaysia: feedstock trading for sustainable aviation fuel (SAF) and biofuels, and ship biofuel supply together with traditional bunkering services. The feedstock trading arm holds the necessary licenses to source and trade raw materials used in SAF and biofuel production, supported by an established network of suppliers and customers. Its bunkering operations include a license to supply both conventional bunker fuel and biofuels within Malaysian waters.This strategic investment aligns with growing global emphasis on environmental, social, and governance (ESG) considerations and evolving regulatory requirements in the maritime and aviation sectors. CBL’s financial resources and operational expertise in marine fuel logistics are expected to support GMH’s expansion, complementing it to scale its feedstock trading activities and explore opportunities to supply SAF-related producers in Malaysia.Malaysia is seeing increased investment in sustainable fuel infrastructure, with new commercial-scale SAF production facilities opening and planned in the country. These developments further underscore the potential for feedstock demand in the region.In the bunkering segment, GMH’s license positions the combined group to develop traditional and biofuel bunkering supply capabilities at key Malaysian ports, including Port Klang—one of the world’s top ten ports by throughput. This builds on CBL’s existing bunkering facilitation services and supports the industry’s transition toward lower-carbon marine fuels.Dr. Teck Lim Chia, Chairman and Chief Executive Officer of CBL, commented: “This acquisition represents a measured step to broaden our presence in the sustainable energy supply chain while leveraging our core strengths in marine fuel services. We look forward to working with the GMH team to support the responsible growth of these businesses in line with market developments.”The transaction is expected to enhance CBL’s long-term positioning in the evolving marine and energy sectors without altering the Company’s primary focus on its established bunkering facilitation activities.About the Banle GroupCBL International Limited (Nasdaq: BANL) is the listing vehicle of Banle Group, a reputable marine fuel logistic company based in the Asia Pacific region that was established in 2015. We are committed to providing customers with one-stop solution for vessel refueling, which is referred to as bunkering facilitator in the bunkering industry. We facilitate vessel refueling mainly through local physical suppliers in over 70 major ports covering Australia, Belgium, China, Hong Kong, India, Japan, Korea, Malaysia, Mauritius, Netherlands, Panama, the Philippines, Singapore, Taiwan, Thailand, Turkey and Vietnam, as of 17 April, 2026. The Group actively promotes the use of sustainable fuels and is awarded with the ISCC EU and ISCC Plus certifications, as well as EcoVadis Silver Medal.For more information about our company, please visit our website at: https://www.banle-intl.com.Forward-Looking StatementsCertain statements in this announcement are not historical facts but are forward-looking statements. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “could,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan,” “should,” “would,” “future,” “outlook,” “potential,” “project” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding estimates and forecasts of other performance metrics and projections of market opportunity. They involve known and unknown risks and uncertainties and are based on various assumptions, whether or not identified in this press release and on current expectations of BANL’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of BANL. Some important factors that could cause actual results to differ materially from those in any forward-looking statements could include changes in domestic and foreign business, fuel prices and tariffs, market, financial, political and legal conditions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the SEC.CBL INTERNATIONAL LIMITED(Incorporated in Cayman Islands with limited liabilities)For more information, please contact:CBL International LimitedEmail: investors@banle-ntl.com Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
More
万利集团收购绿燃控股有限公司多数股权 ACN Newswire

万利集团收购绿燃控股有限公司多数股权

吉隆坡, 2026年4月22日 - (亚太商讯 via SeaPRwire.com) - 万利集团(以下简称"万利"或"集团")之上市实体 CBL International Limited(以下简称"公司"或"CBL")(美国纳斯达克交易所代码:BANL),亚太地区知名燃油供应服务商,今日宣布收购英属维尔京群岛注册公司绿燃控股有限公司("绿燃")50.5%的多数股权。CBL的全资子公司作为《股份出售及购买协议》(简称"SPA")的直接签约方,而CBL并非该协议的签约方,因此CBL向卖方提供公司担保,以确保其子公司履行SPA项下的付款义务。绿燃在马来西亚经营两项互补业务:可持续航空燃料(SAF)和生物燃料的原料贸易,以及船舶生物燃料供应兼传统燃料油加注服务。其原料贸易部门持有所必要的国际认证资质以便采购和交易SAF及生物燃料生产所需原材料,并拥有成熟的供应商与客户网络。燃料油加注业务则持有当地政府发出的许可证,可在马来西亚水域供应传统船用燃料及生物燃料。此次战略投资符合全球日益重视环境、社会和治理(ESG)以及海事、航空领域监管要求不断演变的趋势。CBL的财务资源及船用燃料物流运营专长预计将助力绿燃业务扩张,使其能够扩大原料贸易规模,并探索向马来西亚SAF相关生产企业供应原材料的业务。马来西亚可持续燃料的基础设施投资日益增加,该国已有新的商业规模SAF生产设施投入运营,并有更多项目正在规划中。这些发展进一步凸显了该地区对原料的潜在需求。在燃料油加注业务方面,绿燃的供应资质令集团得以在包括巴生港在内的马来西亚主要港口发展传统燃料和生物燃料的供应能力。巴生港是全球吞吐量前十的港口之一。这将依托CBL现有的燃料油加注服务,支持行业迈向低碳船用燃料转型。CBL集团主席兼行政总裁谢威廉博士评论道:"此次收购是在可持续能源供应链上采取稳健拓展的一步,并充分利用了我们在船用燃料服务方面的核心优势。我们期待与绿燃团队合作,支持这些业务按照市场发展实现负责任增长。"此次交易预计将增强CBL在不断演变的海洋与能源领域的长期定位,同时不会改变公司对现有加燃料服务业务的核心专注。关于万利集团万利集团成立于2015年,以 CBL International Limited(纳斯达克:BANL)在纳斯达克股票市场上市。我们致力于为客户提供一站式燃油供应服务,被业内称为燃油供应服务商。截至2026年4月17日,我们主要通过当地实体供货商为船舶提供燃油加注服务,遍布澳大利亚、比利时、中国、香港、印度、日本、韩国、马来西亚、毛里裘斯、荷兰、巴拿马、菲律宾、新加坡、台湾、泰国、土耳其和越南,共覆盖超过70个港口。集团积极推动可持续燃料的使用,并已取得ISCC EU 和 ISCC Plus 认证,以及EcoVadis银牌。如欲瞭解更多信息,請到集團網站 https://www.banle-intl.com 瀏覽。前瞻性声明本公告中的某些陈述并非历史事实,而是前瞻性陈述。前瞻性陈述一般使用"相信"、"可能"、"可以"、"将要"、"估计"、"继续"、"预期"、"打算"、"期望"、"计划"、"应该"、"将会"、"未来"、"展望"、"潜力"、"项目"等类似词语来预测或表达未来事件或趋势或不属于历史事项的陈述,但不使用这些词语并不意味着陈述并非前瞻性。这些前瞻性陈述包括但不限于对其他绩效指标的估计和预测,以及对市场机会的预测。这些信息涉及已知和未知的风险和不确定性,并基于各种假设(无论本新闻稿中是否指明)以及BANL管理层的当前预期,而非对实际业绩的预测。这些前瞻性陈述仅供说明目的,不得被任何投资者作为且不得被依赖为对事实或可能性的担保、保证、预测或确凿陈述。实际事件和情况难以或不可能预测,也会与假设不同。许多实际事件和情况不在BANL的控制范围内。一些重要因素可能导致实际结果与任何前瞻性陈述存在实质性差异,包括国内外商业、燃料价格及关税、市场、金融、政治和法律环境的变化。公司没有义务公开更新或修改任何前瞻性陈述来反映随后发生的事件或情况或预期的变化,除非法律要求。尽管公司认为该等前瞻性陈述中表达的预期合理,但不能向您保证此类预期最终正确无误。公司提醒投资者实际结果可能与预期结果存在重大差异,并鼓励投资者细阅公司的注册声明和向SEC提交的其他文件所载可能影响其未来业绩的其他因素。CBL INTERNATIONAL LIMITED (注册于开曼群岛的有限责任公司)如需更多信息,請聯繫:CBL International Limited電郵:investors@banle-intl.com Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
GMG Appoints New Chief Production Growth Officer and Provides Update on Global Production Plans ACN Newswire

GMG Appoints New Chief Production Growth Officer and Provides Update on Global Production Plans

Brisbane, Queensland, Australia--(ACN Newswire via SeaPRwire.com - April 22, 2026) - Graphene Manufacturing Group Ltd (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") is pleased to announce that Stuart Watson — former global Head of Technical Development for Rio Tinto Ltd. (ASX: RIO), one of the largest mining and mineral production companies in the world, has joined GMG as Chief Production Growth Officer.Stuart has over 30 years of global leadership experience in metals and mining and oil and chemicals, including 20 years at Rio Tinto, across operations, sales and marketing, mergers and acquisitions, and technology development and innovation. Career highlights include:Leading and delivering multiple major transformation programs valued over US$5 Billion and merger and acquisition deals valued at US$1 Billion.Directing US$1 Billion in global technology and research & development spend to create breakthrough growth options and projectsBuilding high-performing global teams across Asia, Europe, and North AmericaStuart has a Master of Business Administration (MBA) - Henley Management College, UK; is a Chartered Engineer - Institute of Chemical Engineers (IChemE), has a Masters of Engineering, Chemical Engineering (First Class Honours) — Imperial College, University of London and Ecole Nationale Supérieure d'Ingénieurs de Génie Chimique (ENSIGC), Toulouse, France.Craig Nicol, CEO & Managing Director of the Company, commented "We welcome Stuart to the GMG team - he is a great addition to the Senior Executive Team for both executive leadership and delivery capability. I will enjoy working with Stuart to expand our production across our graphene and graphene products around the world."Jack Perkowski, Non-Executive Chairman and Director of the Company, commented: "On behalf of the board I welcome Stuart to the team and look forward to the progress around expanding our production capability into North America."Operations UpdateGMG is focused on delivering its Gen 2.0 Graphene Production Project (the "Gen 2.0 Project") by end of June 2026 — which is expected to produce at least 10 tonnes per annum of graphene at its headquarters in Richlands, Queensland, Australia.Once the Gen 2.0 Project is commissioned and operating. GMG plans to replicate and establish other production plants around the world to enable scaled production for potential sales, diversify and lower production risks, and in the end, reduce operating costs by locating the plant in countries with lower operating costs, including low cost natural gas — one of GMG's key production input costs.Currently, GMG is planning three potential expansion projects — two in North America (potentially one in US and one in Canada) in addition to an expansion production project in Australia. GMG proposes to mature these projects and expand production in line with sales for all of its products.The expansion program for GMG includes the following 5 production plants:Graphene Production (from natural gas)Coating Blend Plant (for the graphene coating THERMAL-XR®)Lubricant Blend Plant (for the graphene lubricant additive G® LUBRICANT)Graphene Slurry Plant (for the SUPA G Lithium-Ion Battery Additive)Battery Assembly Plant (for the Graphene Aluminium Ion Battery)Figure 1To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/293781_d1c07d1d84356a2d_001full.jpgAbout GMG:GMG is an Australian based clean-technology company which develops, makes and sells energy saving and energy storage solutions, enabled by graphene manufactured via in house production process. GMG uses its own proprietary production process to decompose natural gas (i.e. methane) into its natural elements, carbon (as graphene), hydrogen and some residual hydrocarbon gases. This process produces high quality, low cost, scalable, 'tuneable' and low/no contaminant graphene suitable for use in clean-technology and other applications.The Company's present focus is to de-risk and develop commercial scale-up capabilities, and secure market applications. In the energy savings segment, GMG has initially focused on graphene enhanced heating, ventilation and air conditioning ("HVAC-R") coating (or energy-saving coating) which is now being marketed into other applications including electronic heat sinks, industrial process plants and data centres. Another product GMG has developed is the graphene lubricant additive focused on saving liquid fuels initially for diesel engines.In the energy storage segment, GMG and the University of Queensland are working collaboratively with financial support from the Australian Government to progress R&D and commercialization of graphene aluminium-ion batteries ("G+AI Batteries"). GMG has also developed a graphene additive slurry that is aimed at improving the performance of lithium-ion batteries.GMG's 4 critical business objectives are:Produce Graphene and improve/scale cell production processesBuild Revenue from Energy Savings ProductsDevelop Next-Generation BatteryDevelop Supply Chain, Partners & Project Execution CapabilityFor further information please contact:Craig Nicol, Chief Executive Officer & Managing Director of the Company at craig.nicol@graphenemg.com, +61 415 445 223Leo Karabelas at Focus Communications Investor Relations, leo@fcir.ca, +1 647 689 6041Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this news release.Cautionary Note Regarding Forward-Looking StatementsThis news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian and U.S. securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends", "believes" "expects" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or will "potentially" or "likely" occur. This information and these statements, referred to herein as "forward‐looking statements", are not historical facts, are made as of the date of this news release and include without limitation, statements as to GMG's focus on, and the timing and production expectations of, the Gen 2 Project, intentions regarding the number, purpose and location of expansion projects, intentions to de-risk and develop commercial scale-up capabilities, GMG's focus in the energy savings segment, GMG's intentions for the use of graphene lubricant additive on saving liquid fuels, expectations for R&D and commercialization of G+AI Batteries, GMG's ability to improve the performance of lithium-ion batteries and GMG's critical business objectives.Such forward-looking statements are based on a number of assumptions of management, including the patent and potential market size of G® LUBRICANT. Additionally, forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of GMG to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation that GMG does not receive or receive on a timely basis the fully signed consent notice from the and the risk factors set out under the heading "Risk Factors" in the Company's annual information form dated November 4, 2025 available for review on the Company's profile at www.sedarplus.ca.Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/293781 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
OMRON Healthcare and Tricog Health strengthen collaboration in India with Tricog CardioCheck (TCC) JCN Newswire

OMRON Healthcare and Tricog Health strengthen collaboration in India with Tricog CardioCheck (TCC)

KYOTO, Japan, Apr 22, 2026 - (JCN Newswire via SeaPRwire.com) - OMRON Healthcare Co., Ltd., a global leader in clinically proven medical devices for home health monitoring and treatment, today announced the integration of its ECG-enabled upper arm blood pressure monitors with Tricog Health Pte. Ltd.’s clinically validated AI-powered cardiac triage service, Tricog CardioCheck (TCC). The service is scheduled for rollout at health centers across India from April 2026. Tricog CardioCheck (TCC) enables ECG data recorded using OMRON Healthcare’s Complete™ blood pressure monitors with integrated ECG monitoring to be transmitted to the cloud and analyzed by Tricog’s AI algorithms. Within approximately 10 seconds, the system provides a three-level risk assessment, supporting patient triage and timely clinical evaluation.Results are displayed via a dedicated smartphone application designed for healthcare professionals, allowing front-line care providers to review patient risk levels in real time and quickly determine the need for further examination, even where a cardiology specialist is not immediately available.Cardiovascular disease represents a growing public health challenge in India, with the number of patients projected to increase from approximately 110 million today to 230 million by 2050. At the same time, access to specialized care remains limited, with far fewer cardiology specialists per capita than Japan or the United States and limited access to facilities equipped for advanced cardiac testing.While early identification can be crucial to the effective management of cardiovascular conditions such as heart failure and heart attacks, helping to reduce the risk of serious complications including strokes, many cases go undetected until overt symptoms begin to develop.By integrating ECG measurement into routine blood pressure monitoring at clinics, Tricog CardioCheck (TCC) supports the identification of patients whose underlying conditions may otherwise go undiagnosed. Furthermore, the system enables cardiovascular screening to be incorporated into existing workflows without significantly increasing operational burden, facilitating earlier detection and more timely referral for further evaluation.Since its initial investment in Tricog in fiscal year 2023, OMRON Healthcare has continued to strengthen its partnership with the company in order to address key healthcare challenges in India. Through ongoing collaboration, both companies aim to expand access to innovative diagnostic solutions and contribute to improving cardiovascular health outcomes across the country.About OMRON HealthcareCommitted to advancing health and empowering people worldwide to live life to the fullest, OMRON Healthcare is a global leader in the field of clinically proven, innovative medical equipment for home health monitoring and treatment. Aiming to realize its vision, “Going for ZERO, Preventive Care for the Health of Society,” the company develops products for cardiovascular condition management, respiratory care, and pain therapy. Building on this, it has introduced a new digital health ecosystem that bridges patients and healthcare professionals, helping to reduce cerebro-cardiovascular events, the worsening of respiratory diseases, and limitations caused by chronic pain.With over 400 million units sold globally, OMRON provides the world's most recommended blood pressure monitors by healthcare professionals. Throughout its history, OMRON Healthcare has striven to improve lives and contribute to a better society by developing innovations that help people prevent, treat, and manage their medical conditions, providing products and services in over 130 countries.For more information, please visit: Website: https://healthcare.omron.com/LinkedIn: https://www.linkedin.com/company/omron-healthcare-co-ltd-/Media enquiriesThis press release is disseminated by Kyodo PR on behalf of OMRON Healthcare. For more information or for interview opportunities, please contact:OMRON Healthcare Press Desk: omronhealthcare-pr@kyodo-pr.co.jp Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
More
TMX Group Announces Agreement to Acquire Cboe Australia and Cboe Canada ACN Newswire

TMX Group Announces Agreement to Acquire Cboe Australia and Cboe Canada

Transaction will create a global powerhouse for mining finance and reduce complexity and costs for Canadian market participantsAcquisition will strengthen TMX's ability to serve clients across the capital markets ecosystem, expands global presence, accelerates growth strategyAnalyst webcast and conference call on Wednesday, April 22, 2026 at 8:00am EDT to discussToronto, Ontario--(ACN Newswire via SeaPRwire.com - April 22, 2026) - TMX Group Limited (TSX: X) (TMX Group) announced today an agreement to acquire Middlebury Holdings Pty. Limited (Cboe Australia) and Cboe Canada Holdings, ULC (Cboe Canada) from Cboe Global Markets, Inc. for US$300 million ($409 million*) in total consideration, a transaction that will bolster TMX's ability to serve clients across the capital markets ecosystem, expand the company's global presence, and accelerate the company's growth strategy, while reducing cost and complexity for Canadian market participants."We are tremendously excited to announce the acquisition of Cboe Australia and Cboe Canada, a deal that represents a unique opportunity to strengthen our domestic marketplace for clients and the entire stakeholder ecosystem, while expanding the reach and impact of our presence in a region of the world we know well," said John McKenzie, Chief Executive Officer, TMX Group. "We look forward to working with our industry partners to ensure a smooth transition, and to exploring innovative ways to serve the needs of issuers and investors across the Australian market, while continuing to seek out opportunities to accelerate our enterprise growth strategy."Cboe Australia and Cboe Canada offer equities trading venues, listing venues and market data solutions. Cboe Australia is an innovative securities exchange offering companies strategic tailored support for public market listings, including ETFs, as well as structured products and warrants, and providing a trading venue for brokers and investors with efficient and cost-effective access to local and global investment opportunities. Cboe Australia was also recently granted a license for corporate listings. Cboe Canada includes MATCHNow, NEO-L, NEO-N, and NEO-D, as well as ETF, CDR and corporate listings."The teams at Cboe Australia and Cboe Canada have delivered consistent performance and built resilient, high-quality markets," said Craig Donohue, Chief Executive Officer, Cboe Global Markets. "These businesses are well positioned for their next chapter, and we will work closely with TMX, our local regulators, and our clients to ensure a seamless transition."Transaction HighlightsTMX's acquisition of Cboe Australia will bring together the world's leading mining and energy transition financing ecosystems, unlocking potential to innovate for a growing global client base.TMX's acquisition of Cboe Canada enhances the quality of client experience across domestic equities marketplaces:Increasing efficiency of access to capital and liquidity for Canadian issuers, andReducing direct and indirect costs for participants, while improving execution quality and resiliency.Transaction expected to be accretive to adjusted earnings per share within the first 12 months of closing, excluding synergies.Revenue growth expected to be in-line with TMX's long-term financial objectivesCombined Cboe Canada and Cboe Australia businesses delivered revenue of approximately $87 million in 2025, and adjusted EBITDA of approximately $25 million**.Further Transaction DetailsThe purchase of each business is subject to regulatory approvals and customary closing conditions in Australia and Canada. The two components of this acquisition, Cboe Australia and Cboe Canada, are expected to close separately, each after required approvals have been obtained.Canaccord Genuity and Macquarie Capital are acting as financial advisors to TMX Group. FGS Longview is acting as strategic communications advisor to TMX Group.*Based on USD/CAD exchange rate of 1.3644 at April 21, 2026. Actual amounts in Canadian dollars are subject to change.**Based on average AUD/CAD of 0.90 for 2025. Cboe Australia and Canada revenue and EBITDA are compilations of financial information provided to us for the Cboe entities as of December 31, 2025. The Cboe financial information is unaudited and prepared in accordance with IFRS (Cboe Canada) or Australian Accounting Standards (Cboe Australia) for public companies.Teleconference / Audio WebcastTMX Group will host a teleconference / audio webcast to discuss the transaction.Time: 8:00 a.m. - 9:00 a.m. ET on Wednesday, April 22, 2026Participants may access the conference call via the webcast link: https://www.gowebcasting.com/14669.The audio webcast of the conference call and investor presentation will also be available on TMX Group's website at www.tmx.com, under Investor Relations.Alternatively, participants may join the live call by dialing 1-833-752-4317 or 1-647-846-2266.An audio replay of the conference call will be available at 1-855-669-9658 or 1-412-317-0088, [access code 6830744].Caution Regarding Forward-Looking InformationThis press release of TMX Group Limited ("TMX Group", "us", "we", "our") contains "forward-looking information" (as defined in applicable Canadian securities legislation) that is based on expectations, assumptions, estimates, projections and other factors that management believes to be relevant as of the date of this press release. Often, but not always, such forward-looking information can be identified by the use of forward-looking words such as "plans", "expects", "projects", "is expected", "projected", "budget", "scheduled", "targeted", "estimates", "forecasts", "intends", "anticipates", "believes", or variations or the negatives of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved or not be taken, occur or be achieved. Forward-looking information, by its nature, requires TMX Group to make assumptions and is subject to significant risks and uncertainties which may give rise to the possibility that our expectations or conclusions will not prove to be accurate and that our assumptions may not be correct. Examples of forward-looking information in this press release include, but are not limited to, the anticipated benefits of the transactions to TMX Group, Cboe Canada and Cboe Australia; the expected impact on TMX Group's earnings and Adjusted earnings per share; expectations regarding the revenue growth of Cboe Canada and Cboe Australia; the ability to integrate Cboe Canada and Cboe Australia into TMX Group and the potential synergies; the expected impact on TMX's long-term growth strategy and transformational objectives; the potential for geographic expansion; the ability for TMX Group to accelerate Cboe Canada and Cboe Australia's growth; the timing and receipt of regulatory approval; and closing of the transaction, each of which is subject to a number of significant risks and uncertainties. These risks include, but are not limited to: competition from other exchanges or marketplaces, including alternative trading systems and new technologies, on a national and international basis; dependence on the economies of Canada, the United States and Australia; adverse effects on our results caused by global economic conditions (including geopolitical events, interest rate movements or threats of recession) or uncertainties including changes in business cycles that impact our sector; failure to retain and attract qualified personnel; geopolitical and other factors which could cause business interruption; dependence on information technology; vulnerability of our networks and third party service providers to security risks, including cyber attacks; failure to properly identify or implement our strategies; regulatory constraints; constraints imposed by our level of indebtedness, risks of litigation or other proceedings; dependence on adequate numbers of customers; failure to develop, market or gain acceptance of new products; failure to close and effectively integrate acquisitions, including the Cboe Canada and Cboe Australia acquisition, to achieve planned economics or divest underperforming businesses; currency risk; adverse effect of new business activities; adverse effects from business divestitures; not being able to meet cash requirements because of our holding company structure and restrictions on paying inter-corporate dividends; dependence on third party suppliers and service providers; dependence of trading operations on a small number of clients; risks associated with our clearing operations; challenges related to international expansion; restrictions on ownership of TMX Group common shares; inability to protect our intellectual property; adverse effect of a systemic market event on certain of our businesses; risks associated with the credit of customers; cost structures being largely fixed; the failure to realize cost reductions in the amount or the time frame anticipated; dependence on market activity that cannot be controlled; the regulatory constraints that apply to the business of TMX Group and its regulated subsidiaries, costs of on exchange clearing and depository services, trading volumes (which could be higher or lower than estimated) and the resulting impact on revenues; future levels of revenues being lower than expected or costs being higher than expected.Forward-looking information is based on a number of assumptions which may prove to be incorrect, including, but not limited to, assumptions with respect to the impact of the cost of acquisition financing on adjusted earnings per share; assumptions in connection with the ability of TMX Group to successfully compete against global and regional marketplaces and other venues; business and economic conditions generally; exchange rates (including estimates of exchange rates from Canadian dollars to the U.S. dollar, British pound sterling, or Australian dollar), commodities prices, the level of trading and activity on markets, and particularly the level of trading in TMX Group's key products; business development and marketing and sales activity; the continued availability of financing on appropriate terms for future projects; changes to interest rates and the timing thereof; productivity at TMX Group, as well as that of TMX Group's competitors; market competition; research and development activities; the successful introduction and client acceptance of new products and services; successful introduction of various technology assets and capabilities; the impact on TMX Group and its customers of various regulations; TMX Group's ongoing relations with its employees; and the extent of any labour, equipment or other disruptions at any of its operations of any significance other than any planned maintenance or similar shutdowns.In addition to the assumptions outlined above, forward looking information related to long term revenue CAGR objectives, and long term adjusted earnings per share CAGR objectives are based on assumptions that include, but not limited to:TMX Group's success in achieving growth initiatives and business objectives;continued investment in growth businesses and in transformation initiatives including next generation technology and systems;no significant changes to our effective tax rate, and number of shares outstanding;organic and inorganic growth in recurring revenuemoderate levels of market volatility over the long term;level of listings, trading, and clearing consistent with historical activity;economic growth consistent with historical activity;no significant changes in regulations;continued disciplined expense management across our business;continued re-prioritization of investment towards enterprise solutions and new capabilities;free cash flow generation consistent with historical run rate; anda limited impact from inflation, rising interest rates and supply chain constraints on our plans to grow our business over the long term including on the ability of our listed issuers to raise capital.While we anticipate that subsequent events and developments may cause TMX Group's views to change, TMX Group has no intention to update this forward-looking information, except as required by applicable securities law. This forward-looking information should not be relied upon as representing TMX Group's views as of any date subsequent to the date of this press release. TMX Group has attempted to identify important factors that could cause actual actions, events or results to differ materially from those current expectations described in forward-looking information. However, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended and that could cause actual actions, events or results to differ materially from current expectations. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. These factors are not intended to represent a complete list of the factors that could affect TMX Group. Important additional information identifying risks and uncertainties and other factors is contained in TMX Group's 2025 Annual Report under the headings entitled "Caution Regarding Forward-Looking Information" and "Enterprise Risk Management" which may be accessed at tmx.com in the Investor Relations section under Regulatory Filings.Non-GAAP Financial MeasuresThis press release includes references to financial measures that are not defined by GAAP. Although such non-GAAP measures are calculated according to accepted industry practice, such measures disclosed in this press release may be different from non-GAAP measures used by other companies. This data is intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with GAAP. While TMX Group believes these measures provide investors with greater transparency and supplemental data relating to the transaction, readers are cautioned that these non-GAAP measures are not alternatives to measures determined in accordance with GAAP and should not, on their own, be construed as indicators of TMX Group's or Cboe Canada and Cboe Australia's future performance or profitability. Readers should not rely on any single financial measure when evaluating TMX Group's business or that of Cboe Canada and Cboe Australia. We use non-GAAP measures and non-GAAP ratios that do not have standardized meanings prescribed by GAAP and are, therefore, unlikely to be comparable to similar measures presented by other companies. Management uses these measures, and excludes certain items, because it believes doing so provides investors a more effective analysis of underlying operating and financial performance, including, in some cases, our ability to generate cash and our ability to repay debt. Management also uses these measures to more effectively measure performance over time, and excluding these items increases comparability across periods. The exclusion of certain items does not imply that they are non-recurring or not useful to investors.Adjusted earnings per share provided above is a non-GAAP ratio and does not have a standardized meaning prescribed by GAAP and is therefore unlikely to be comparable to similar measures presented by other companies. TMX Group presents Adjusted EPS and excludes, among other things, acquisition, integration, and related items; amortization of intangibles related to acquisitions; strategic re-alignment expenses; dispute, litigation and related items; and other items as disclosed in TMX Group's 2025 Annual Report. For more information on Adjusted EPS, including definitions and explanations of how these measures provide useful information, refer to Non-GAAP Measures in TMX Group's 2025 Annual Report.Adjusted EBITDA is calculated as net income excluding interest expense, income tax expense, depreciation and amortization, acquisition, integration, and related costs, one-time income (loss), and other significant items that are not reflective of the underlying business operations of Cboe Canada and Cboe Australia. Cboe Canada and Cboe Australia Adjusted EBITDA is a compilation of financial information provided to us for Cboe Canada and Cboe Australia entities as of December 31, 2025. The Cboe Canada and Cboe Australia financial information is unaudited and prepared in accordance with IFRS (Cboe Canada) or Australian Accounting Standards (Cboe Australia) for public companies. Adjusted EBITDA for Cboe Canada and Cboe Australia excludes certain items such as discontinued operations, transfer pricing, unrealized gains / losses, and one-time employee costs.About TMX Group (TSX: X) TMX Group operates global markets, and builds digital communities and analytic solutions that facilitate the funding, growth and success of businesses, traders and investors. TMX Group's key operations include Toronto Stock Exchange, TSX Venture Exchange, TSX Alpha Exchange, The Canadian Depository for Securities, Montréal Exchange, Canadian Derivatives Clearing Corporation, TSX Trust, TMX Trayport, TMX Datalinx, TMX VettaFi and TMX Newsfile, which provide listing markets, trading markets, clearing facilities, depository services, technology solutions, data products and other services to the global financial community. TMX Group is headquartered in Toronto and operates offices across North America (Montréal, Calgary, Vancouver and New York), as well as in key international markets including London, Singapore, and Vienna. For more information about TMX Group, visit www.tmx.com. Follow TMX Group on X: @TMXGroup.For more information please contact:Catherine KeeHead of Media RelationsTMX Group416-671-1704catherine.kee@tmx.comAmanda TangHead of Investor RelationsTMX Group416-895-5848amanda.tang@tmx.com To view the source version of this press release, please visit https://www.newsfilecorp.com/release/293729 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
Hengrui Pharma Reports Q1 2026 Results with Revenue and Net Profit Growth ACN Newswire

Hengrui Pharma Reports Q1 2026 Results with Revenue and Net Profit Growth

HONG KONG, Apr 22, 2026 - (ACN Newswire via SeaPRwire.com) - Hengrui Pharma reported steady growth in the first quarter of 2026. In Q1 2026, the Company recorded revenue of RMB 8.14 billion, up 12.98% year-over-year, while net profit attributable to shareholders increased by 21.78% to RMB 2.28 billion. Innovative drugs remained the key growth driver, generating RMB 4.53 billion in revenue, up 25.75% year-over-year and accounting for 61.69% of total pharmaceutical sales.The Company continued to advance its innovation-driven strategy with sustained R&D investment and solid pipeline progress. R&D investments in Q1 2026 totaled RMB 2.22 billion, representing for approximately 27.32% of revenue.During the period, three innovative products and new indications were approved in China, which included an anti-PD-L1/TGF-βRII bi-functional fusion protein and an indication expansion for HER2-targeting ADC.In terms of pipeline advancement, the Company obtained 26 clinical trial approvals and had 8 new drug applications accepted in China across key therapeutic areas including oncology, metabolic, cardiovascular, and immunological diseases.Business development has become a recurring and increasingly important growth driver, with RMB 787 million in out-licensing revenue recognized during the quarter, primarily from the collaboration with GSK. Since 2023, Hengrui Pharma has completed 12 overseas business development transactions, including out-licensing, NewCo structures, and strategic alliance models.A key milestone during the period was the successful Nasdaq listing of Kailera Therapeutics (NASDAQ: KLRA), a NewCo company built around Hengrui Pharma’s GLP-1-based assets. This milestone reflects continued progress in executing the Company’s NewCo strategy, with Hengrui and Kailera working together to advance the global development of the GLP-1 portfolio.Looking ahead, Hengrui Pharma will remain committed to innovation and globalization, strengthening its pipeline and advancing the development and commercialization of innovative therapies to benefit patients worldwide. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More

赤子城科技: 2026 年 Q1 收入超 20 亿 同比增长33.0%~39.6%

EQS via SeaPRwire.com / 2026-04-22 / 17:40 UTC+8 4 月 22 日,赤子城科技发布第一季度未经审核营运数据公告。截至 2026 年 3 月 31 日止三个月,公司预期录得收入约人民币 20.30~21.30 亿元,较 2025 年同期增长约33.0%~39.6%。其中社交业务收入约人民币 17.85~18.65 亿元,同比增长约31.3%~37.2%;创新业务收入约人民币 2.45~2.65 亿元,同比增长约 46.7%~58.7%,整体保持强劲增长态势。 社交业务壁垒加深,旗舰产品竞争力提升 公告显示,公司社交业务收入同比稳健增长,主要归因于公司持续推进全球化布局及 AI 全链路应用,带动旗舰产品实现稳步增长。第一季度,公司持续推进“产品复制+国家复制”策略,巩固在中东北非、东南亚等优势市场的头部地位,同时以旗舰产品为“先锋”,在拉美、欧洲、日韩等高增长及高价值新市场持续发力,完善全球社交娱乐版图。 2026 年,公司旗舰产品保持强劲发展。陪伴社交平台 SUGO 在细分赛道的竞争力进一步增强,游戏社交平台 TopTop 在 GCC 等区域的市场地位不断提升。据 Sensor Tower 数据,一季度 SUGO 位居中东社交网络收入排行榜第 5 位,较 2025 年四季度排名提升 2 位;TopTop 位列同一榜单第 6 位。此外,在 Sensor Tower 一季度“中国非游戏应用海外收入排行榜”中,SUGO 位列第 13 位,排名环比提升。 在新市场,SUGO、TopTop亦保持扩张态势。在拉美市场,SUGO 位居 2026 年一季度社交网络收入排名第 12 位,较 2025 年四季度排名提升 8 位。TopTop 在日本、欧洲等高价值市场取得积极进展,今年一季度多次进入日本 App Store 休闲游戏免费榜 Top 10。 目前,SUGO 作为全球在线社交行业的“黑马”,正从一款区域性陪伴社交标杆产品,崛起为兼具全球影响力和卓越商业化效率的社交平台;TopTop 则持续发挥 UGC 生态优势,积极布局发达国家市场,不仅在沙特阿拉伯等 GCC 市场成长为“国民级应用”,在全球市场同品类产品中亦位居前列。 同时,公司多元人群社交业务亦稳步发展。全球化多元人群社区 HeeSay 在优势市场东南亚的影响力稳步加深,稳居越南、菲律宾等国家 App Store 社交应用畅销榜 TOP 10。 华西证券研报指出,全球社交网络与游戏类 App 在下载量、使用时长、商业变现三个维度均表现突出,赤子城科技在全球范围内的布局将持续受益,成长的长期确定性凸显。 创新业务发展强劲,AI 赋能收入高速增长 创新业务在今年一季度展现出了强劲的发展动力。公告显示,高增长主要得益于在 AI 驱动下,公司积极投入的短剧业务实现快速增长。 一季度,公司短剧业务有序推进,覆盖欧美等全球多市场,验证了内容创作及爆款打造的全链路能力。在此基础上,公司大力布局 AI 短剧,依托 AI 技术放大内容产能、丰富题材类型、优化制作成本,驱动短剧成为创新业务新的增长推动力。 日前,公司短剧业务正式接入 Seedance 2.0,成为首批合作平台之一。同时,通过与 TikTok 等平台联合运营,公司短剧内容的全球影响力进一步提升。根据 TikTok 发布的短剧第一季度分账报告,公司旗下爆款剧首月分账规模即达到平台单剧第 2。 近年来,公司持续推进 AI 技术深度应用,全面赋能研发、运营等核心业务场景。其中,自研多模态算法模型 Boomiix 持续升级,提升社交匹配精准度与运营智能化水平;自研 AI 智能数据平台思语大幅缩短数据查询、异动分析、报告生成等流程的响应周期;自研 AI 智能设计平台 KIVI 大幅提升虚拟礼物、投放素材等的产出效率与内容丰富度。此外,公司积极拓展消费级 AI 应用,孵化 AI 游戏社区产品 Aippy,探索以 AI 创造情绪价值的新路径。据悉,目前 Aippy 累计下载量已超 200 万。此外,公司推出的 AI Agent 支付项目 NUSD Pay,目前已完成核心系统搭建并进入商业化运营阶段。 日前,公司宣布未来两年内将斥资约 3 亿港元进行股份回购,并拟用于本公司员工股权激励计划,或根据适用法律法规及上市规则予以注销。董事会认为,在当前情况下实施股份回购,有助于体现公司对自身业务前景的信心,并将为公司带来裨益及为股东创造价值。 3 月 6 日,公司正式获纳入港股通合资格证券名单,拓宽内地投资者的参与渠道。纳入以来,公司市场关注度及交易活跃度显著提升,截至 4 月 21 日,日均成交额超 1.8 亿港元,较纳入前 3 个月水平提升约 2 倍。随着纳入港股通,公司股东结构持续优化,市场影响力进一步增强,为公司长期发展提供有力支撑。 2026-04-22 此财经新闻稿由EQS via SeaPRwire.com转载。本公告内容由发行人全权负责。原文链接: http://www.todayir.com/sc/index.php
More

致丰新能源与中国土木泰国公司签署泰国新能源项目战略合作备忘录 共同推动泰国本地新能源产业发展

EQS via SeaPRwire.com / 2026-04-22 / 17:17 UTC+8 (香港 – 2026年 4月 22日) 香港领先的工业电子零件及产品制造及销售企业 – 致丰工业电子集团有限公司(「致丰集团」或「集团」,股份代号:1710),今日宣布其子公司致丰新能源(广州)有限公司(「致丰新能源」)与中国土木工程集团(泰国)有限公司(「中国土木泰国公司」)近日在泰国正式签署《新能源项目合作备忘录》,就共同推动泰国本地新能源产业发展达成战略合作意向。 随着泰国推进能源结构转型与交通电动化进程,对绿色电力、分布式储能及清洁交通方案的需求持续上升。致丰新能源在新能源整体解决方案及产品研发制造方面具备专长,而中国土木泰国公司则深耕泰国市场,在绿色基础设施及绿色园区开发领域拥有丰富项目储备与本地资源。双方会尽快整合优势,共同抓住泰国及周边国家的新能源发展机遇。根据备忘录,双方目前正就泰国新能源项目合作进行商务磋商,合作方式将以整合双方优质资源、在泰国共同开发新能源产业为主。 致丰工业电子集团主席黄思齐先生表示:「中国土木泰国公司在泰国基础设施和园区开发领域深耕多年,拥有优秀的项目资源与本地运营能力。我们希望通过本次合作备忘录,将致丰新能源在源网荷储一体化、新能源产品研发及本地化制造等方面的专长,与中国土木泰国公司的项目与渠道优势紧密结合,在泰国共同打造标杆示范项目。展望未来,致丰新能源将以务实的步伐推进各项试点和标杆项目,为泰国的绿色低碳转型贡献力量,并为双方创造长期稳健的合作价值。」 中国土木工程集团(泰国)有限公司郑斌表示:「致丰新能源在新能源技术与装备制造领域具备成熟经验与创新能力,能为泰国市场提供具有竞争力的绿色能源与电动出行解决方案。本次签署合作备忘录,是双方在泰国拓展新能源业务的重要起点。中国土木期待与致丰新能源携手,在绿色园区、绿色校园及交通枢纽新能源配套等领域率先实现突破,逐步形成可复制、可推广的合作模式,并在未来探索更广泛的「一带一路」市场协同机遇。」 - 完 – 关于致丰工业电子集团有限公司(股份代号:1710.HK) 致丰集团是香港领先的工业电子零件及产品制造商,拥有超过40年的行业经验,专注于高品质电源产品的生产与销售,业务涵盖节能、医疗等关键领域。作为香港电子工业供应商中首家荣获工业4.0成熟度1i级认证的企业,集团以智能化制造与创新技术为核心,为全球客户提供高效可靠的解决方案,并成为众多国际知名品牌的长期合作伙伴,客户群主要遍及欧美市场。 面对全球ESG(环境、社会与治理)趋势与零碳转型需求,致丰集团积极布局可持续能源领域,透过旗下自主品牌Deltrix拓展可再生能源、储能技术及绿色基础设施业务。市场版图延伸至中亚与东南亚,服务范畴包括: 电动车充电解决方案 光伏储能系统 智能电源管理系统 充电网络基础设施 凭借深厚的技术积累与前瞻性的产业布局,致丰集团持续推动绿色科技创新,致力成为全球能源转型中的关键参与者,实践企业永续发展愿景。 此新闻稿由金通策略有限公司代致丰工业电子集团有限公司发布。 如有任何查询,请联络: DLK Advisory 金通策略 电邮: pr@dlkadvisory.com 电话: +852 2857 7101 2026-04-22 此财经新闻稿由EQS via SeaPRwire.com转载。本公告内容由发行人全权负责。原文链接: http://www.todayir.com/sc/index.php
More
At the Forefront of Green Transportation: A Deep Dive into Smart Green Mobility Share Inc.’s (SGM.s) Globalization Strategy SeaPRwire

At the Forefront of Green Transportation: A Deep Dive into Smart Green Mobility Share Inc.’s (SGM.s) Globalization Strategy

New York, NY – April 22, 2026 – (SeaPRwire) – Against the global backdrop of pursuing “Net-Zero Emissions,” the micromobility market is experiencing explosive growth. As a dark horse in this field, Smart Green Mobility Share Inc. (SGM.s) has become a focal point of industry attention, thanks to its unique “Global Industrial Integration” model and rapid pace of expansion. From Pure Operations to Ecosystem Empowerment Unlike traditional bike-sharing companies, SGM.s is not content with being just a vehicle operator. In 2026, SGM.s took a critical step by launching its “Global Industrial Resource Integration Plan.” This strategy marks SGM.s’s transformation into an “Integrated Mobility Ecosystem Provider.” By consolidating top-tier upstream manufacturing resources and downstream global distribution channels, SGM.s is breaking the stalemate of long, inefficient chains in the traditional mobility industry. It does not just export products; it exports standardized intelligent systems (AI+IoT) and global operational expertise, providing partners with one-stop “Turn-key” solutions. Core Competitive Advantages: Digital Operations and Deep User Engagement The secret to SGM.s’s success lies in its ultimate pursuit of “efficiency”: AI-Driven Grid Management: Relying on its self-developed intelligent system, SGM can accurately predict vehicle demand across different time slots and locations. This predictive deployment significantly reduces vehicle idle rates, leading the industry in per-unit profitability. Innovative Value-Sharing Mechanism: SGM’s “Online Vehicle Deployment Program” breaks the traditional boundaries between the enterprise and the user. Users are not just consumers; they are maintainers and beneficiaries of the ecosystem. This high level of user stickiness not only lowers operation and maintenance costs but also garners broader social support and brand loyalty for the company. Impressive Results: The “SGM.s Speed” of Global Expansion To date, SGM.s’s footprint spans over 280 cities worldwide. Scale Effect: 300,000 vehicles in operation form a solid competitive moat. Environmental Contribution: The cumulative reduction in carbon emissions has become the company’s most persuasive ESG (Environmental, Social, and Governance) calling card, giving it a natural advantage in securing international green capital. Conclusion: Reshaping the Boundaries of Future Mobility Essentially, SGM.s is utilizing advanced digital technology to empower traditional transportation. As the 2026 Industrial Integration Plan moves forward, SGM.s is poised to take a more dominant position in the future landscape of shared transportation. For observers and investors, SGM.s represents more than just a shared mobility platform; it embodies a future business paradigm of “Green Energy + Digital Intelligence + Global Collaboration.” Company link: https://sgmpw.com/#/register/7665222 Media contact Organization: Smart Green Mobility Share Inc Connect: SGM.s Team Email: support@sgm.lol Website: https://sgm.lol
More
MHI Marine Machinery & Equipment and Mitsubishi Shipbuilding Obtain Approval in Principle (AiP) for the Basic Design of a Methane Oxidation Catalyst System for Marine LNG-Fueled Engines from Classification Society ClassNK JCN Newswire

MHI Marine Machinery & Equipment and Mitsubishi Shipbuilding Obtain Approval in Principle (AiP) for the Basic Design of a Methane Oxidation Catalyst System for Marine LNG-Fueled Engines from Classification Society ClassNK

TOKYO, Apr 22, 2026 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Heavy Industries Marine Machinery & Equipment Co., Ltd. (MHI-MME) and Mitsubishi Shipbuilding Co., Ltd., both part of the Mitsubishi Heavy Industries (MHI) Group, have obtained Approval in Principle (AiP)(1) from Nippon Kaiji Kyokai (ClassNK) for the basic design of a methane oxidation catalyst system for marine LNG (liquefied natural gas)-fueled engines(2), jointly developed with Daihatsu Infinearth Mfg. Co., Ltd. A presentation ceremony was held today at Sea Japan 2026, an international maritime exhibition being held at Tokyo Big Sight in Koto-ku, Tokyo.The methane oxidation catalyst system subject to the AiP oxidizes methane slip (unburned methane) contained in the exhaust gas of marine engines. Methane has a high global warming potential among greenhouse gases (GHGs),(3) and therefore the ability to suppress its emissions is a significant advantage of this system. The system was developed with MHI-MME's catalyst design and manufacturing technology at its core, combined with Mitsubishi Shipbuilding's shipboard installation technology, and Daihatsu Infinearth's engine optimization technology.Verification testing of the catalyst system is currently being conducted in cooperation with Nippon Yusen Kabushiki Kaisha (NYK Line), with a full-scale demonstrator mounted on the KEYS Azalea, an LNG bunkering vessel(4) owned and operated by KEYS Bunkering West Japan Ltd. (KEYS). Initial measurements during the verification testing confirmed the expected performance of the exhaust gas treatment equipment, achieving a methane oxidation rate of more than 90% for the system alone.Following the acquisition of AiP and the confirmation of the expected performance through verification on an actual ship (initial measurements), the partner companies plan to further accelerate development toward commercialization of the system.MHI Group is making strategic efforts to strengthen its energy transition business. As part of this strategy, MHI-MME and Mitsubishi Shipbuilding will continue their efforts to reduce GHG emissions from marine vessels amid the growing global urgency for decarbonization, thereby contributing to the improvement of the environmental performance of ships on a global scale.(1) Approval in Principle (AiP) indicates that a certification body has reviewed the basic design of the subject equipment and confirmed that it meets technical requirements and relevant safety standards.(2) Methane oxidation is a chemical reaction in which methane (CH4) is converted into carbon dioxide (CO2) and water (H2O) through reaction with oxygen.(3) Greenhouse gases (GHGs) include carbon dioxide (CO2), methane (CH4), and nitrous oxide (N2O). The catalyst system for this demonstration test only targets methane slip.(4) LNG bunkering vessels are small ships that supply LNG fuel to LNG-fueled vessels.About MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
More

Luxury NEV Maker Seres Delivers Sustained Profitability and Strong Dividends

HONG KONG, Apr 22, 2026 - (ACN Newswire via SeaPRwire.com) - Recently, Seres Group (9927.HK), a leading luxury new energy vehicle (NEV) enterprise in China, officially released its 2025 annual results. During the Reporting Period, the Company recorded revenue of approximately RMB164.89 billion, representing a year-on-year increase of 13.63% and reaching a new record high. Net profit attributable to shareholders amounted to approximately RMB5.96 billion, marking the second consecutive year of profitability. These strong results underscore the Company’s high-quality growth trajectory and highlight its resilience and core competitiveness in the luxury NEV segment.The massive product sales volume is the most direct and powerful testament to Seres’ market competitiveness. In 2025, AITO, the luxury brand under Seres, achieved a cumulative annual delivery volume of over 420,000 units. Among these, annual deliveries of the AITO M9 exceeded 110,000 units, securing its position as the sales champion in the RMB500,000+ price luxury car market for two consecutive years in 2024 and 2025; the AITO M8 recorded annual deliveries of over 150,000 units, firmly holding the top spot on the sales charts for RMB400,000+ price models since its launch; and the AITO M7 delivered over 110,000 units for the year, winning the title of “National SUV of the Year.” This highlights the AITO brand’s formidable brand strength and high user recognition in the luxury NEV market.A comprehensive business layout serves as a vital cornerstone and reliable safeguard for Seres to withstand market fluctuations and achieve sustainable growth. In 2025, the Company firmly implemented its dual-strategy layout of range-extension electric vehicles and battery electric vehicles, which closely aligns with the diversified demands of the NEV market, enabling all-round breakthroughs amid fierce competition. Seres ranked first in China’s range-extension segment with a market share of 37.5%. Meanwhile, the sales proportion of its battery electric models continued to rise, forming a sound development pattern in which technical strength and market competitiveness improved in tandem.Generous and steady dividends reflect Seres’ commitment to rewarding shareholders and sharing development achievements, and also serve as a tangible demonstration of the Company’s sound operation. In 2025, the Board of Directors proposed a final dividend for the year ended 31 December 2025 of RMB0.8 per share (tax inclusive), representing a total proposed cash dividend of approximately RMB1.9 billion. This initiative actively rewards the trust and support of all shareholders, reflects the Company’s firm confidence in its future development, and further strengthens investors’ expectations for the Company’s long-term growth.Excellent ESG performance serves as a fundamental underpinning of Seres’ high-quality development and a core competitiveness for the Company’s sustainable growth. In 2025, the Company continued to deepen its ESG governance, integrating ESG philosophy across the full chain of production and operations, R&D and innovation, and supply chain management. Through concrete actions, Seres is advancing the synergistic development of the enterprise, society and the environment.Leveraging robust ESG management practices and remarkable sustainability achievements, Seres was awarded the highest AAA rating by MSCI, demonstrating its corporate value through responsibility and accountability.Driven by technological innovation, guided by customer value, and committed to sustainable development, Seres made steady progress in the luxury NEV segment in 2025, achieving comprehensive advancements in business performance, brand strength, technological capability, and ESG performance. Looking ahead, Seres will continue to deepen its dual-track strategy of range-extension electric and battery electric vehicles, further increase R&D investment, and accelerate technological iteration and product innovation. The Company is committed to continuously leading the upgrade of China’s luxury NEV industry and creating greater value for customers, shareholders, and society. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
NEC Receives Company of the Year recognition in Global Biometric Solutions from Frost & Sullivan JCN Newswire

NEC Receives Company of the Year recognition in Global Biometric Solutions from Frost & Sullivan

TOKYO, Apr 22, 2026 - (JCN Newswire via SeaPRwire.com) - NEC Corporation (NEC; TSE: 6701) becomes the first company in the biometrics industry to receive Frost & Sullivan’s Global Biometric Solutions Company of the Year recognition(1), underscoring its leadership and innovation.Frost & Sullivan(2) bestows Best Practices Awards annually to companies that have achieved outstanding performance in their respective industries based on a rigorous analytical process. This year, NEC has been honored with the most prestigious award, the Company of the Year Award.For this Global Biometric Solutions Award, Frost & Sullivan analysts independently assessed NEC based on two criteria:Visionary Innovation & PerformanceAddressing Unmet Needs; Visionary Scenarios Through Megatrends; Leadership Focus; Best Practices Implementation; and Financial PerformanceCustomer ImpactPrice/Performance Value; Customer Purchase Experience; Customer Ownership Experience; Customer Service Experience; and Brand EquityTara Semon, Security Industry Analyst, Frost & Sullivan, said, "NEC’s achievements reflect a rare blend of technical excellence, ethical leadership, and customer-centric innovation. From pioneering multimodal authentication and ear acoustic to championing self-sovereign identity and responsible AI usage, the company has consistently delivered solutions that meet the evolving needs of a global market."Its deployments across public safety, education, and consumer experiences demonstrate the versatility and impact of its technologies. NEC’s commitment to research, ethics, and global expansion positions it as a beacon of excellence in the biometric solutions industry."In the future, NEC will continue to focus on replacing physical identity verification methods and physical security, as well as accelerating the development and provision of solutions that can be adapted to new use cases in an ever-growing digital society.NEC is thoroughly committed to following the NEC Group AI and Human Rights Principles(3) in its use of AI, biometric data, and other data, placing the highest priority on privacy and respect for human rights.NEC offers end-to-end digital transformation (DX) services, from strategy and concept consulting to implementation-focused offerings, based on the three pillars of business models, technology, and organization/talent. Additionally, in its shift from a traditional systems integrator to a "Value Driver," NEC restructured its value creation model under the name "NEC BluStellar"(4), which leverages NEC's cutting-edge technologies, developed and refined through years of experience and proven cross-industry expertise, aiming to transform business models, address social challenges, resolve management issues faced by customers, and lead them into a brighter future.For more information about third-party recognition of NEC’s biometric authentication, please visit here.(1) Frost & Sullivan Best Practices 2026 Recognition Recipients(2) Frost & Sullivan - The Transformational Growth Company(3) "NEC Group AI and Human Rights Principles" https://www.nec.com/en/press/201904/global_20190402_01.html(4) NEC BluStellar is a value creation model that leverages NEC’s cutting-edge technologies, developed and refined through years of experience and proven cross-industry expertise. It aims to transform business models, address social challenges, resolve management issues faced by customers, and lead them into a brighter future.About NECThe NEC Group leverages technology to create social value and promote a more sustainable world where everyone has the chance to reach their full potential. NEC Corporation was established in 1899. Today, the NEC Group’s approximately 110,000 employees utilize world-leading AI, security, and communications technologies to solve the most pressing needs of customers and society.For more information, please visit https://www.nec.com. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
More
Everest Medicines Announces Positive First-in-Human Data for Personalized mRNA Cancer Vaccine EVM16 at AACR 2026 ACN Newswire

Everest Medicines Announces Positive First-in-Human Data for Personalized mRNA Cancer Vaccine EVM16 at AACR 2026

HONG KONG, Apr 22, 2026 - (ACN Newswire via SeaPRwire.com) - Apr 20, Everest Medicines announced that the first-in-human (FIH) clinical trial data of EVM16, a proprietary personalized mRNA cancer vaccine, were presented at the 2026 American Association for Cancer Research Annual Meeting (AACR 2026). The data include results from EVM16 as a monotherapy and in combination with the PD-1 inhibitor tislelizumab in patients with advanced solid tumors. The results demonstrated that EVM16 has a favorable safety and tolerability profile, robust immunogenicity, and promising preliminary efficacy in patients with advanced solid tumors, supporting its further clinical development.The clinical trial (EVM16CX01, NCT06541639) was conducted jointly by Peking University Cancer Hospital and Fudan University Shanghai Cancer Center, with the first patient dosed in March 2025. EVM16CX01 is a first-in-human (FIH), dose-escalation, and expansion study evaluating the safety, tolerability, immunogenicity, and preliminary efficacy of EVM16 injection as a monotherapy and in combination with tislelizumab in patients with advanced solid tumors. The study follows a 3+3 dose-escalation design across three dose levels (0.1 mg, 0.3 mg, and 1.0 mg). Eligible patients are those with advanced or recurrent solid tumors who have failed standard of care and have at least one measurable target lesion. Patients receive 2 doses of EVM16 monotherapy once every two weeks, followed by combination therapy of EVM16 and tislelizumab. As of December 7, 2025, a total of 9 patients had been enrolled.No dose-limiting toxicities (DLTs) were observed. All patients experienced at least one investigational product (IP) related adverse event (AE), all of which were Grade ≤ 2 and resolved spontaneously. EVM16 elicited strong neoantigen-specific T cell responses in 8 of 9 patients, which showed a dose-dependent trend. A gastroesophageal junction cancer patient who failed 3 prior lines of systemic therapy achieved a confirmed partial response and a PFS of 126 days. Another 2 patients achieved stable disease. A non-small cell lung cancer patient who failed 3 prior lines of systemic therapy achieved a PFS of 88 days, and an esophageal squamous cell carcinoma patient who failed 3 prior lines of systemic therapy has been followed up for 112 days to date and has not experienced disease progression.“As a novel personalized mRNA cancer vaccine, EVM16 has demonstrated encouraging clinical development potential in its first-in-human clinical trial,” said Professor Shen Lin, Director of the Gastrointestinal Oncology Department at Beijing Cancer Hospital and Chair of the Gastric Cancer Expert Committee of the Chinese Society of Clinical Oncology. “The data show a favorable safety and tolerability profile in patients with advanced solid tumors, with no dose-limiting toxicities (DLTs) observed. Importantly, EVM16 stimulated neoantigen-specific T cell responses with a dose-dependent trend, highlighting its consistent immune activation capability. Preliminary anti-tumor activity signals, including partial response (PR) and stable disease (SD), were observed in patients who had failed multiple lines of standard-of-care therapies, suggesting potential clinical activity. These findings provide early clinical validation of EVM16 and reinforce its differentiated mechanism as a personalized mRNA cancer vaccine. While immunotherapies, including checkpoint inhibitors, have transformed the treatment landscape in selected tumor types, most patients, particularly those with heavily pretreated advanced solid tumors, still represent a significant unmet medical need. Personalized mRNA cancer vaccines represented by EVM16 may help expand the population benefiting from immunotherapy and provide additional treatment options.” “The favorable safety, tolerability, immunogenicity, and preliminary efficacy results for EVM16 provide initial evidence of its therapeutic potential and support the clinical value of our in-house mRNA platform,” said Mr. Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “Patients with advanced solid tumors, particularly those who have failed multiple lines of therapy, continue to suffer from limited treatment options. As our first in-house developed personalized mRNA cancer vaccine, EVM16 demonstrates the ability to induce immune activation and generate neoantigen-specific T cell responses, which may help reduce the risk of tumor metastasis or recurrence. This further underscores its potential as a novel approach in cancer immunotherapy. This project is powered by EVER-NEO-1, Everest’s proprietary AI-based neoantigen prediction algorithm. It analyzes patient-specific tumor mutations to identify highly immunogenic neoantigens and support the design of personalized mRNA vaccine candidates. The algorithm incorporates iterative learning capabilities designed to continuously improve neoantigen prediction accuracy and selection efficiency. Leveraging our leading mRNA platform, we will continue to advance the clinical development of EVM16 and bring this innovative therapy to more patients.”Everest Medicines has localized its clinically validated proprietary AI+mRNA platform, establishing an end-to-end integrated platform spanning antigen design, mRNA sequence optimization, lipid nanoparticles (LNP) targeted delivery and scalable manufacturing, with the potential to address significant unmet medical needs globally.EVM16 is a novel personalized therapeutic mRNA cancer vaccine in-house developed by Everest. It contains neoantigens with high immunogenicity potential, predicted based on the unique tumor mutations of each patient using Everest’s proprietary AI-based neoantigen prediction algorithm, EVER-NEO-1. The vaccine is designed to encode dozens of tumor neoantigens. The vaccine uses a lipid nanoparticle (LNP) delivery system to efficiently deliver neoantigen-encoded mRNA in vivo, activating neoantigen-specific tumor-killing T cells and inhibiting tumor growth.From an investment and market perspective, personalized cancer vaccines are in an early stage of breakthrough. According to Grand View Research, the global personalized cancer vaccine market is projected to reach $1.45 billion by 2030, with a staggering compound annual growth rate (CAGR) of 44.86% from 2025 to 2030. Myguide Securities points out that mRNA cancer vaccines have the potential to achieve pan-cancer coverage while offering the advantages of high accessibility, “off-the-shelf” availability, and personalization. As a highly promising new form of immunotherapy, it can enter clinical use as adjuvant therapies through extensive combinations, gradually unlocking a market space worth tens of billions of dollars.Against this backdrop, Everest Medicines is accelerating its strategic positioning in this field, progressively building a research and development pipeline with global competitiveness. Leveraging its proprietary AI+mRNA platform and its leading clinical position in China, Everest Medicines is currently at a critical juncture for industrialization and valuation growth. The upcoming readout of first-in-human (FIH) clinical trial data for EVM16 is expected to further release clinical and commercial potential, continuing to attract focus from the market and investors, and helping the company achieve a significant leap in value within the immunotherapy sector. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
云顶新耀mRNA个性化肿瘤治疗性疫苗EVM16于AACR 2026公布首次人体数据积极 展现良好安全性、较强免疫原性与初步疗效 ACN Newswire

云顶新耀mRNA个性化肿瘤治疗性疫苗EVM16于AACR 2026公布首次人体数据积极 展现良好安全性、较强免疫原性与初步疗效

香港, 2026年4月22日 - (亚太商讯 via SeaPRwire.com) - 4月20日,云顶新耀宣布在2026年美国癌症研究协会(AACR)年会上公布其自主研发的mRNA个性化肿瘤治疗性疫苗EVM16单药治疗及联合PD-1抑制剂(替雷利珠单抗)治疗晚期实体瘤的首次人体临床试验(FIH)数据。结果显示出良好的安全性和耐受性、显著的免疫原性及积极的初步疗效信号,支持进一步临床开发的推进。据悉,该临床试验由北京大学肿瘤医院与复旦大学附属肿瘤医院联合发起(EVM16CX01,NCT06541639),并于2025年3月完成首例患者给药。EVM16CX01是一项评估EVM16注射液单药及联合PD-1抑制剂治疗对晚期或复发实体瘤患者的安全性、耐受性、免疫原性和初步疗效的剂量递增及扩展研究,该试验采用3+3 剂量递增设计,包括三个剂量组:0.1 mg、0.3 mg和1.0 mg。入选患者为经标准治疗失败的晚期或复发性实体瘤患者,且至少有一个可测量靶病灶。患者将接受2次EVM16单药治疗(每两周一次),随后接受EVM16联合替雷利珠单抗治疗。截至2025年12月7日,共入组9例患者。安全性和耐受性方面,EVM16未观察到剂量限制性毒性(DLT)。所有患者均报告至少一次与研究药物相关的不良事件,均为2级及以下,且均可自行缓解。 EVM16在9例患者中有8例诱导出强烈的新抗原特异性T细胞免疫反应,并显示出剂量依赖性趋势。初步临床疗效方面,一例既往接受过三线系统治疗失败的胃食管结合部癌患者达到确认的部分缓解(PR),无进展生存期(PFS)为126天。另有2例患者达到疾病稳定(SD),其中一例既往接受过三线系统治疗失败的非小细胞肺癌患者PFS为88天,另一例既往接受过三线系统治疗失败的食管鳞癌患者截至数据截止日已随访112天,尚未观察到疾病进展。北京大学肿瘤医院消化肿瘤内科主任、中国临床肿瘤学会胃癌专家委员会主任委员沈琳教授表示:"EVM16作为一款新型mRNA个性化肿瘤治疗性疫苗,在首次人体临床试验中展现出良好的临床开发潜力。数据显示,该疫苗在晚期实体瘤患者中整体安全性与耐受性良好,未观察到剂量限制性毒性。在免疫学层面,EVM16能够诱导新抗原特异性T细胞应答,并呈现一定剂量依赖趋势,提示其具有较强的免疫激活能力。在疗效探索方面,临床试验在既往接受多线标准治疗失败的患者中观察到初步抗肿瘤活性信号,包括部分缓解(PR)及疾病稳定(SD),显示其免疫学作用机制具有改善临床获益的潜力。总体而言,该临床试验初步验证了EVM16通过新抗原驱动T细胞应答实现肿瘤免疫激活的临床价值,为其后续临床开发提供了重要依据。当前,尽管免疫检查点抑制剂已显著改善部分肿瘤的治疗格局,但总体获益人群仍有限,尤其是在多线治疗失败的晚期实体瘤患者中仍存在显著未满足需求。EVM16所代表的mRNA个性化肿瘤治疗性疫苗治疗路径,有望在现有免疫治疗基础上进一步拓展受益人群,并带来更多治疗选择。"云顶新耀首席执行官罗永庆表示:"非常高兴看到EVM16的首次人体临床试验数据在AACR大会上公布。此次公布的在晚期实体瘤患者中展现出良好的安全性与耐受性、疗效及作用机制等方面的积极结果,初步验证了EVM16的治疗潜力和云顶新耀自研mRNA平台的临床价值。对于晚期实体瘤患者而言,尤其是多线治疗失败人群,仍然缺乏有效且具有针对性的治疗选择。EVM16作为公司自主研发的mRNA个性化肿瘤治疗性疫苗,具备诱导免疫激活并产生新抗原特异性T细胞应答的潜力,有望预防肿瘤转移或复发,代表了肿瘤免疫治疗的重要探索方向。该项目基于公司自主研发的EVER-NEO-1‘妙算’肿瘤新抗原人工智能算法系统。该系统可基于患者肿瘤特异性突变进行分析,识别具有较高免疫原性的肿瘤新抗原,并生成相应的mRNA疫苗设计方案,且具备自我迭代优化能力,以持续提升新抗原预测与筛选效率。依托国际领先的mRNA平台,我们将加速推进EVM16后续临床开发工作,推动该创新疗法惠及更多患者。"云顶新耀已成功将经过临床验证的自研AI+mRNA平台本地化,构建了一个涵盖从抗原设计、mRNA序列优化、脂质纳米颗粒(LNP)靶向递送技术到产业化生产的端到端全产业链平台,具备了在全球范围内解决巨大未满足医疗需求的潜力。EVM16是公司自主研发的mRNA个性化肿瘤治疗性疫苗,根据每位患者特有的肿瘤细胞突变,通过EVER-NEO-1"妙算"系统识别具有较高免疫原性的肿瘤新抗原,并设计编码数十种肿瘤新抗原的mRNA治疗性疫苗。EVM16通过LNP靶向递送系统在体内进行高效的抗原呈递,激活患者自身的新抗原特异性T细胞免疫,进而达到杀伤肿瘤细胞和治疗癌症的目的。从投资与市场维度来看,个体化肿瘤疫苗尚处早期突破期。根据Grand View Research的预测,全球个性化癌症疫苗市场规模2030年将达14.5亿美元,2025-2030年复合增长率,高达44.86%。麦高证券指出,mRNA肿瘤疫苗有望实现泛癌种覆盖,同时兼具高可及性、现货化与个性化优势。作为极具潜力的新型肿瘤免疫疗法,其可通过广泛联用,以辅助疗法切入临床,逐步打开数百亿美元的市场空间。在此背景下,云顶新耀在该领域的布局正加速落地,逐步构建具备全球竞争力的研发管线。依托自主AI+mRNA平台与国内率先布局的临床身位,云顶新耀正处于产业化与估值成长的关键节点。本次EVM16首次人体临床试验(FIH)数据的读出,有望进一步释放临床与商业化潜力,进一步吸引市场及投资者持续聚焦,助力公司在肿瘤免疫赛道实现长足的价值跨越。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
MHIEC Completes Improvement of Core Equipment at Municipal Solid Waste Incineration Facility in Kagoshima City JCN Newswire

MHIEC Completes Improvement of Core Equipment at Municipal Solid Waste Incineration Facility in Kagoshima City

Hokubu Waste-to-Energy PlantTOKYO, Apr 22, 2026 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Heavy Industries Environmental & Chemical Engineering Co., Ltd. (MHIEC), a part of Mitsubishi Heavy Industries (MHI) Group, has recently completed the improvement of core equipment for Hokubu Waste-to-Energy Plant, a municipal solid waste incineration facility in Kagoshima City. The work consisted of renovation of the stoker type incinerators, capable of processing 530 tonnes per day (tpd) (1), to extend the plant's service life and reduce CO2 emissions. This was a project spanning a six-year period from fiscal 2020 to fiscal 2025.The Hokubu Waste-to-Energy Plant was originally designed and constructed by MHI, and completed in March 2007. It comprises two units of stoker type incinerators, each with processing capacity of 265 tpd, plus related equipment, delivering power generation capacity of 8,700 kW.Under the refurbishment work, upgrades have been made to deteriorated major equipment, to achieve stable combustion and operation over the long term. Additionally, a low-temperature catalyst, a proprietary technology of MHIEC, was introduced to the SCR (Selective Catalytic NOx Reduction) system to improve the heat recovery rate (2), a low excess air ratio incineration technology (3) was adopted to improve combustion and the efficiency of the boiler, and the output of the steam turbines was increased from 8,700 kW to 10,005 kW, which will reduce CO2 emissions by approximately 33.1% per year.MHIEC took over MHI's waste treatment plant business in 2008, acquiring the technological development capabilities in environmental systems and broad-ranging expertise in the construction and operation of waste management facilities both in Japan and overseas that MHI honed over many years. A strength of this company is its ability to propose total solutions from construction to operation based on its extensive track record. Going forward, MHIEC will continue to proactively make proposals to extend the life of existing waste treatment facilities, take measures against global warming, and reduce lifecycle costs (LCC) such as maintenance and management costs to contribute to the decarbonization of energy through the collection of energy from waste.(1) A stoker-type incinerator injects air from beneath heat-resistant fire grates, mixing the waste and other material by pushing it up, and allowing for efficient incineration. It is the most common system used for municipal solid waste.(2) An SCR system removes nitrous oxides (NOx), an air pollutant in exhaust gases, and typically operates at a high temperature. With MHIEC's technology, a catalyst that can remove NOx at low temperatures was introduced to the SCR system, eliminating the need to heat the exhaust gas to a high temperature and increasing the heat recovery rate.(3) The volume of air required for combustion is suitably distributed to reduce the volumes of combusted air and exhaust gas, increasing the efficiency of the boiler and decreasing the energy consumption of the induced draft fan.About MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
More
MHIEC Completes Improvement of Core Equipment at Municipal Solid Waste Incineration Facility in Sendai City JCN Newswire

MHIEC Completes Improvement of Core Equipment at Municipal Solid Waste Incineration Facility in Sendai City

Matsumori Waste-to-Energy PlantTOKYO, Apr 22, 2026 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Heavy Industries Environmental & Chemical Engineering Co., Ltd. (MHIEC), a part of Mitsubishi Heavy Industries (MHI) Group, has recently completed the improvement of core equipment for Matsumori Waste-to-Energy Plant, a municipal solid waste incineration facility in Sendai City. MHIEC received the contract for the project from Sendai City in 2021, with work carried out over a five-year period from fiscal 2021 to fiscal 2025. The renovation of the stoker-type incinerators(1) with total processing capacity of 600 tons per day (tpd) will extend the operational life of the facility and reduce CO2 emissions.The Matsumori Waste-to-Energy Plant was originally designed and constructed by MHI, and completed in August 2005. It comprises three units of stoker-type incinerators, each with processing capacity of 200 tpd, plus related equipment, delivering power generating capacity of 17,500 kW.Under the refurbishment work, upgrades have been made to major equipment superannuated after more than 15 years in operation, to achieve stable combustion and operation over the long term. In addition, the thermal efficiency of the boiler has been enhanced with the introduction of EGR-PLUS®, a new combustion control system using an exhaust gas recirculation technology.(2) Further, a part of the soot blower that removes ash from the boiler tube has been changed from a conventional steam type to a pressure-wave (shock pulse) type,(3) reducing the amount of steam used for ash removal and allowing more steam for power generation, thereby boosting power generating capacity. These renovations have achieved a reduction in CO2 emissions of 12.1% annually.MHIEC took over the waste treatment plant business from MHI in 2008, acquiring technological development capabilities in environmental systems and broad-ranging expertise in the construction and operation of waste management facilities both in Japan and overseas. This extensive experience allows MHIEC to provide comprehensive solutions, from plant construction to operations. Going forward, MHIEC will continue to proactively make proposals to extend the life of existing waste treatment facilities, take measures against global warming, and reduce lifecycle costs (LCC) such as maintenance and management costs to contribute to the decarbonization of energy through the collection of energy from waste.(1) A stoker-type incinerator injects air from beneath heat-resistant fire grates, mixing the waste and other material by pushing it up, and allowing for efficient incineration. It is the most common system used for municipal solid waste.(2) Exhaust Gas Recirculation (EGR) is a technology to send exhaust gas from the incinerator back into the combustion chamber, promoting complete combustion and reducing nitrogen oxide (NOx) emissions. MHIEC's EGR-PLUS® is a leading-edge combustion control system that combines EGR with low air ratio (the amount of air actually sent to the incinerator divided by the minimum amount of air theoretically required for incineration) combustion technology to reduce the environmental impact, and achieve a stable increase in the amount of electricity sold.(3) A pressure-wave (shock pulse) type soot blower is a device that removes ash from pipes by igniting a mixture of methane and oxygen and firing it into the combustion chamber from an injection nozzle, creating a pressure wave that breaks up ash deposits and causes fine vibrations on the pipe surface.About MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
More
迈威生物冲刺港股上市:BD驱动价值释放 差异化创新管线重塑增长曲线 ACN Newswire

迈威生物冲刺港股上市:BD驱动价值释放 差异化创新管线重塑增长曲线

香港, 2026年4月22日 - (亚太商讯 via SeaPRwire.com) - 在创新药研发竞争日趋激烈的当下,具备自主研发能力与全产业链布局的中国生物制药企业正加速走向国际资本市场。迈威(上海)生物科技股份有限公司(以下简称"迈威生物")于4月20日开启公开招股,拟在香港主板上市,进一步拓展全球研发与商业化网络。2025年,迈威生物在业务拓展领域接连取得里程碑式突破,先后完成多项覆盖小核酸、IL-11靶向疗法及长效G-CSF等前沿技术领域的授权合作,累计潜在总金额超过16亿美元。这一系列合作不仅验证了公司平台的研发实力,也为其后续全球临床开发与商业化提供了充沛的资金支持。正是凭借这些重磅合作的持续落地,迈威生物的全球商业化能力逐步凸显,其技术价值正加速转化为可量化的商业回报。对外授权成果显着,验证全球研发价值迈威生物的研发实力已获得国际制药巨头的真金白银认可,其卓越的商业拓展能力成为驱动公司价值增长的核心引擎。2025年,公司总收入达到6.59亿元人民币,同比增长超过2.3倍。其中,对外授权收入达4.09亿元,同比激增超过6倍,这主要得益于与多家国际知名生物科技公司的重磅合作。2025年6月,公司就9MW3811(一款靶向IL-11的人源化单抗)与谷歌系公司Calico达成独家许可协议,授权其在除大中华区外的全球范围内开发和商业化。Calico长期专注于"抗衰老"及年龄相关疾病的生物学研究,在该领域拥有深厚的技术积累,此次合作将加速9MW3811的全球临床开发,进一步提升其在纤维化疾病及癌症治疗领域的国际影响力。9MW3811靶向的IL-11是一种关键的促纤维化细胞因子,在肺纤维化、皮肤瘢痕、肾纤维化、肝纤维化等多种病理进程中扮演核心角色。目前,9MW3811不仅已获批开展特发性肺纤维化临床试验,更于2025年底成为全球首款进入病理性瘢痕(包括增生性瘢痕和瘢痕疙瘩)治疗临床阶段的IL-11靶向药物,为其未来拓展更多纤维化适应症打开了空间。同年10月,迈威生物进一步拓展技术边界,与专注于NewCo孵化的专业机构Aditum Bio就新型双靶点siRNA候选药物达成独家许可协议。Aditum Bio由前诺华高管创立,以其"精准筛选具有巨大潜力的资产,快速推进至临床概念验证,将项目打造成大型制药企业青睐的收购目标"的成熟模式而闻名。此次合作不仅为迈威生物在小核酸药物领域的前瞻性布局引入了国际顶级专业资本的背书,更重要的是,Aditum Bio高效的临床推进能力将大幅缩短该管线的验证周期,有望加速其临床转化进程。深耕相关领域的合作方往往推进意向明确。迈威生物与Disc Medicine就9MW3011(一款靶向TMPRSS6的单克隆抗体)达成的合作正是这一逻辑的体现。双方于2023年1月签署独家许可协议,合同总价值高达4.1亿美元。9MW3011通过调节铁调素水平控制铁过载,为真性红细胞增多症这一尚无有效改良疗法的罕见血液病提供了全新治疗思路。Disc已于2025年9月启动该产品治疗真性红细胞增多症的II期临床试验,至此公司累计收到首付款及I、II期里程碑付款合计2,500万美元。合作的高效推进不仅验证了靶点价值,也为后续更高金额的开发及商业化里程碑奠定了基础。与聚焦早期研发管线的授权合作不同,迈威生物与齐鲁制药围绕已上市产品迈粒生®(长效G-CSF)达成大中华区独家授权合作,借助成熟药企的商业化能力,实现优势互补与风险共担。齐鲁制药在中国肿瘤领域拥有强大的商业化网络和市场渗透能力,双方联手既能加速迈粒生®的市场放量,又能丰富齐鲁制药的产品组合,最大化共享市场红利。技术筑底:源头创新驱动,ADC与TCE双引擎发力密集的BD成果背后,是迈威生物强大的源头创新能力。公司已建立起以自主知识产权的定点偶联技术IDDC™为核心的ADC药物开发平台,以及一体化高效抗体发现平台和T细胞衔接器(TCE)双/三特异性抗体开发平台。其中,IDDC™平台依托四大核心技术DARfinity®(定点偶联)、IDconnect™(稳定连接子分子)、Mtoxin™(新型毒性分子)和LysOnly™(条件释放结构),能够开发出更均匀、更稳定、纯度更高、潜在疗效更好、更安全的优化ADC药物。以核心产品9MW2821(靶向Nectin-4 ADC)为例,该平台通过定点偶联工艺,使产品DAR值均一性超过95%,显著优于传统随机偶联技术,更均一的分子结构带来了更好的稳定性和安全性。值得关注的是,根据美国FDA官网及权威公开资料,已上市的同靶点药物Padcev带有黑框警告,主要涉及严重皮肤反应;而根据迈威生物招股书披露的临床数据,9MW2821在临床试验中展现出良好的安全性,未观察到同类的严重不良事件。疗效方面,9MW2821在尿路上皮癌、三阴性乳腺癌等适应症上均表现出优于Padcev的客观缓解率(ORR)趋势,展现其"同类最佳"潜力。2024年以来,该产品已获得国家药监局突破性疗法认定及FDA多项快速通道与孤儿药资格,国际监管认可度持续提升。迈威生物ADC平台的另一个代表性产品是7MW4911(靶向CDH17 ADC)。 该产品针对的适应症是国内高发的胃肠道肿瘤,患者基数庞大,现有治疗手段仍存在耐药等局限。为应对这一挑战,7MW4911不仅结合创新单抗Mab0727、新型连接子,还采用了专有的Mtoxin™载荷,这是一种专为克服ABC转运蛋白介导的多药耐药机制而设计的强效DNA拓扑异构酶I抑制剂,能有效杀伤耐药肿瘤细胞。目前,7MW4911单药疗法已于2025年11月在中国启动I期临床试验,并于2026年1月在美国启动I/II期临床试验。在TCE领域,迈威生物也取得了实质性进展。公司的6MW5311(靶向CD3/LILRB4)已于近日向国家药监局提交IND申请并获受理,同时其美国临床试验申请目前处于pre-IND阶段,计划于2026年第二季度向FDA正式递交申请。该管线用于治疗复发/难治性急性髓系白血病、慢性粒单核细胞白血病以及复发或难治性多发性骨髓瘤,其独特优势在于:在无肿瘤环境下对T细胞的结合活性极低,而在肿瘤与T细胞共存的微环境中则对肿瘤细胞表现出强效杀伤作用,从而在保障疗效的同时显著提高了安全性。TCE与ADC在肿瘤治疗中机制互补,前者激活T细胞免疫,后者精准杀伤肿瘤细胞。展望未来,迈威生物有望探索二者的联用方案,在肿瘤领域构建起更为广阔和立体的治疗矩阵,释放巨大的管线协同效应。结语全球肿瘤药物市场预计2032年将突破5,400亿美元,ADC、TCE等新一代抗体类药物正重塑精准治疗格局,罕见病与纤维化等领域仍存在巨大未满足需求。凭借扎实的技术平台、前瞻性的管线布局以及卓越的全球商业拓展能力,随着"A+H"两地上市落地,迈威生物将拥有更灵活的资本工具,加速核心产品的全球多中心临床试验、扩充生产产能、深化国际合作。展望未来,公司不仅有望在尿路上皮癌、宫颈癌、三阴性乳腺癌等领域实现关键上市,更将在纤维化疾病、罕见血液病、核酸药物等新赛道持续布局,成长为辐射全球的创新型生物制药领军企业。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
A new system to track material design processes ACN Newswire

A new system to track material design processes

TSUKUBA, Japan, Apr 22, 2026 - (ACN Newswire via SeaPRwire.com) - Discovering and characterizing new materials is important for unlocking advances in fields like clean energy, advanced manufacturing, and improved infrastructure. Researchers use machine learning and other computational tools to help them, but the trial-and-error nature of the process creates specific challenges. The research produces large amounts of experimental and computational data, and scientists need tools that can track and store not only the results but also the chain of reasoning behind them.A newly developed system tracks and stores not only the results but also the chain of reasoning behind them, allowing researchers to review the decision making process for a greater transparency and reproducibility in materials science research.A new system called pinax, published in the journal Science and Technology of Advanced Materials: Methods, provides precisely those features. Developed by engineers at Japan’s National Institute for Materials Science (NIMS), pinax captures the entire process of developing new materials, including machine learning workflows and decision-making processes. “By formalizing both successful and unsuccessful trial-and-error processes, pinax enhances reproducibility, accountability, and knowledge sharing while maintaining strict data governance,” says Satoshi Minamoto of NIMS, the study’s lead author.The new pinax system consists of three layers: the core machine learning infrastructure (bottom), the provenance recording and tracking that visualises the reasoning behind final results (middle), and the advanced feature layer for materials development (top). Credit: STAM-MMachine learning models are playing an ever-larger role in materials discovery and characterization. While the models are powerful tools, the reasoning processes they use are generally opaque. Researchers don’t know what considerations and trial-and-error processes went into their final predictions. “The system introduced in this study visualizes these invisible processes. This enables others to review, verify, and build upon the path to the conclusions,” says Minamoto.Minamoto highlights the importance of such access in applications where safety, reproducibility, and accountability are important, saying that this work “demonstrates how transparent AI systems can transform scientific discovery into a more reliable, efficient, and socially responsible endeavor.”The team tested pinax using two case studies: one on predicting steel properties and another using transfer learning to predict the thermal conductivity of polymers. The system made it possible to link the model’s performance predictions to the specific data or model aspects that influenced them, and to reproduce complex, multi-stage workflows. “In particular, the transfer-learning example highlights pinax’s ability to track how information flows between intertwined datasets and models, making every step in the reasoning process explicitly traceable,” says Minamoto.The engineers plan to expand pinax towards an autonomous, closed-loop materials discovery system. By integrating pinax’s tracking capabilities with automated experimental and simulation systems, they aim to create a loop that can use data generation, machine learning models, and decision-making systems to systematically and independently carry out the entire research cycle.Further information Satoshi MinamotoNational Institute for Materials Scienceminamoto.satoshi@nims.go.jpPaper: https://doi.org/10.1080/27660400.2026.2629051 About Science and Technology of Advanced Materials: Methods (STAM-M)STAM Methods is an open access sister journal of Science and Technology of Advanced Materials (STAM), and focuses on emergent methods and tools for improving and/or accelerating materials developments, such as methodology, apparatus, instrumentation, modeling, high-through put data collection, materials/process informatics, databases, and programming. https://www.tandfonline.com/STAM-MDr Kazuya SaitoSTAM Methods Publishing Director SAITO.Kazuya@nims.go.jpPress release distributed by Asia Research News for Science and Technology of Advanced Materials. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More